quality control raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Primary hypercortisolism (Cushing's syndrome): excessive levels of cortisol Secondary hypercortisolism (pituitary tumor resulting in Cushing's disease, pseudo-Cushing's syndrome) Primary hypocortisolism (Addison's disease, Nelson's syndrome): insufficient levels of cortisol Secondary hypocortisolism (pituitary tumor, Sheehan's syndrome)
=== Regulation in Britain and the United States === Before the 1920s, regulation in Britain was controlled by pharmacists. Pharmacists who were found to have prescribed opium for illegitimate uses and anyone found to have sold opium without proper qualifications would be prosecuted. With the passing of the Rolleston Act in Britain in 1926, doctors were allowed to prescribe opiates such as morphine and heroin if they believed their patients demonstrated a medical need. Because addiction was viewed as a medical problem rather than an indulgence, doctors were permitted to allow patients to wean themselves off opiates rather than cutting off any opiate use altogether. The passing of the Rolleston Act put the control of opium use in the hands of medical doctors instead of pharmacists. Later in the 20th century, addiction to opiates, especially heroin in young people, continued to rise and so the sale and prescription of opiates was limited to doctors in treatment centres. If these doctors were found to be prescribing opiates without just cause, then they could lose their licence to practice or prescribe drugs. Abuse of opium in the United States began in the late 19th century and was largely associated with Chinese immigrants. During this time the use of opium had little stigma; the drug was used freely until 1882 when a law was passed to confine opium smoking to specific dens. Until the full ban on opium-based products came into effect just after the beginning of the twentieth century, physicians in the US considered opium a miracle drug that could help with many ailments.
=== Lifetime cumulative dose === Bleomycin should not exceed a lifetime cumulative dose greater than 400 units. Pulmonary toxicities, most commonly presenting as pulmonary fibrosis, are associated with doses of bleomycin greater than 400 units.
== Pharmacology == The fenethylline molecule results when theophylline is covalently linked with amphetamine by an alkyl chain. Fenethylline is metabolized by the body to form two drugs, amphetamine (24.5% of oral dose) and theophylline (13.7% of oral dose), both of which are active stimulants. The physiological effects of fenethylline therefore seem to result from a combination of these two compounds, although it is not entirely clear how, and seems to involve a synergistic effect between amphetamine and theophylline produced following metabolism. The pharmacological actions of fenethylline before cleavage also remain poorly established, though it appears to act directly at several serotonin receptors.
Sources: en.wikipedia.org
The four substrates of this enzyme are 3-hydroxyphenylacetic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are homogentisic acid, oxidised NAD+, and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. This enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is 3-hydroxyphenylacetate,NAD(P)H:oxygen oxidoreductase (6-hydroxylating). This enzyme is also called 3-hydroxyphenylacetate 6-monooxygenase. It participates in styrene degradation.
== Influence on the Labour Party == According to political historians, Democratic Left's intellectual framework, rooted in the "New Times" analysis, influenced discussions within the Labour Party during the 1990s. The movement represented a shift away from traditional socialism toward what would become the Third Way politics associated with New Labour. Ideas developed within Marxism Today and carried forward by Democratic Left - particularly around moving beyond class-based politics and embracing post-industrial economic realities - were among those discussed during the Labour Party's ideological debates under Neil Kinnock and Tony Blair. This intellectual influence was facilitated by direct personal connections, as many former CPGB members and "New Times" theorists became advisors to Labour leadership. In 1997, Democratic Left published a series of policy magazines titled Futures in an attempt to address declining membership. The organisation faced internal tensions in 1998 when members of the Trotskyist-dominated Socialist Alliance attempted to join. After blocking this through legal action, Democratic Left's leadership concluded it needed to avoid becoming "stuck in the swamp of sectarian politics." The organisation stated this decision reflected its goal of moving beyond traditional left-wing sectarianism toward a more inclusive, pluralistic approach to progressive politics.
Biological pigments were often difficult to acquire, and the details of their production were kept secret by the manufacturers. Tyrian purple is a pigment made from the mucus of several species of murex snail. Production of Tyrian purple for use as a fabric dye began as early as 1200 BC by the Phoenicians, and was continued by the Greeks and Romans until 1453 AD, with the fall of Constantinople. In the same way as the modern-day Latin alphabet of Phoenician origin, Phoenician purple pigment was spread through the unique Phoenician trading empire. The pigment was expensive and time-consuming to produce, and items coloured with it became associated with power and wealth. This popular idea of purple being elite contributes to the modern day widespread belief that purple is a "royal colour". The colour of textiles from this period provides insight into socio-cultural relationships within ancient societies, in addition to providing insights on technological achievements, fashion, social stratification, agriculture and trade connections. Despite their value to archaeological research, textiles are quite rare in the archaeological record. Like any perishable organic material, they are usually subject to rapid decomposition and their preservation over millennia requires exacting conditions to prevent destruction by microorganisms. Tyrian purple may first have been used by the ancient Phoenicians as early as 1570 BC. It has been suggested that the name Phoenicia itself means 'land of purple'.
Sources: en.wikipedia.org
Experiments manipulating the oxygen content, carbon dioxide content, and pH of bowfin extradural fluid did not affect breathing rate, heart rate, or blood pressure, pointing to a lack of central chemoreceptor regulation. Instead, bowfin respiratory patterns respond to water oxygen content and water temperature, as water temperatures play a role in oxygen content. In the laboratory, bowfin showed an increase in breathing rate when the temperatures were raised above 10 °C. Bowfin also showed an increase in breathing rate when exposed to lower oxygen levels in the water. Herpetologist W. T. Neill reported in 1950 that he unearthed a bowfin aestivating (in a dormant state) in a chamber 4 inches (10 cm) below the ground surface, 8 inches (20 cm) in diameter, 0.25 miles (0.4 km) from a river. Flood levels, of note, had previously reached the area and receded. Not unusually, riverine species like bowfin move into backwaters with flood currents and become trapped when water levels recede. While aestivation is anecdotally documented by multiple researchers, laboratory experiments have suggested, instead, that bowfin are physiologically incapable of surviving more than 3 to 5 days of air exposure, but no field manipulation has been performed. Regardless of the lack of evidence confirming the bowfin's ability to aestivate, bowfin can survive prolonged conditions of exposure to air because they have the ability to breathe air. Their gill filaments and lamellae are rigid in structure, which helps prevent the lamellae from collapsing and aids gas exchange even during air exposure.
Journal of Military History. 65 (3): 617–640. doi:10.2307/2677528. JSTOR 2677528. S2CID 159945703. McEvedy, Colin; Jones, Richard (1978). Atlas of World Population History. Facts on File. ISBN 978-0-87196-402-1. McLynn, Frank (1998). Napoleon: A Biography. Pimlico. ISBN 978-0-7126-6247-5. Munch-Petersen, Thomas (2007). Defying Napoleon: How Britain Bombarded Copenhagen and Seized the Danish Fleet in 1807. Sutton. ISBN 978-0-7509-4280-5. Palmer, Robert Roswell (1941). Twelve who Ruled: The Committee of Public Safety, During the Terror. Princeton University Press. Palmer, Alan (1974). Alexander I: Tsar of War and Peace. Weidenfeld & Nicolson. ISBN 978-0-297-76700-8. Palmer, R. R.; Colton, Joel; Kramer, Lloyd (2013). A History of the Modern World: 11th Edition. McGraw-Hill Higher Education. ISBN 978-0-07-759962-1. Payne, Stanley G. (1973). A History of Spain and Portugal: Eighteenth Century to Franco. Vol. 2. Madison: University of Wisconsin Press. ISBN 978-0299062705. Retrieved 2 May 2021. Philo, Tom (2010), Military and Civilian War Related Deaths Through the Ages, archived from the original on 20 April 2010 Rapport, Mike (2013). The Napoleonic Wars: A Very Short Introduction. OUP Oxford. ISBN 978-0-19-164251-7. Riehn, Richard K. (1990). 1812: Napoleon's Russian Campaign. McGraw-Hill. ISBN 978-0-07-052731-7. Riehn, Richard K. (1991), 1812: Napoleon's Russian Campaign (Paperback ed.), New York: Wiley, ISBN 978-0-471-54302-2 Riley, J. P. (2013). Napoleon and the World War of 1813: Lessons in Coalition Warfighting. Routledge. ISBN 978-1-136-32135-1. Roberts, Andrew (2014).
GST proteins are globular proteins with an N-terminal mixed helical and beta-strand domain and an all-helical C-terminal domain. The porcine pi-class enzyme pGTSP1-1 was the first GST to have its structure determined, and it is representative of other members of the cytosolic GST superfamily, which contain a thioredoxin-like N-terminal domain as well as a C-terminal domain consisting of alpha helices. Mammalian cytosolic GSTs are dimeric, with both subunits being from the same class of GSTs, although not necessarily identical. The monomers are approximately 25 kDa in size. They are active over a wide variety of substrates with considerable overlap. The following table lists all GST enzymes of each class known to exist in Homo sapiens, as found in the UniProtKB/Swiss-Prot database.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.